Journal of Neuro-Oncology

, 91:199

Survival benefit of Boron neutron capture therapy for recurrent malignant gliomas

Authors

    • Department of NeurosurgeryOsaka Medical College
    • Cancer Intelligence Care System, Inc.
  • Shinji Kawabata
    • Department of NeurosurgeryOsaka Medical College
  • Kunio Yokoyama
    • Department of NeurosurgeryOsaka Medical College
  • Toshihiko Kuroiwa
    • Department of NeurosurgeryOsaka Medical College
  • Hiroyuki Michiue
    • Department of NeurosurgeryOkayama University
  • Yoshinori Sakurai
    • Particle Radiation Oncology Research Center, Research Reactor Institute, Kyoto University
  • Hiroaki Kumada
    • Department of Research Reactor and Tandem Accelerator, Nuclear Science Institute, Japan Atomic Energy Agency
  • Minoru Suzuki
    • Particle Radiation Oncology Research Center, Research Reactor Institute, Kyoto University
  • Akira Maruhashi
    • Particle Radiation Oncology Research Center, Research Reactor Institute, Kyoto University
  • Mitsunori Kirihata
    • Department of AgricultureOsaka Prefectural University
  • Koji Ono
    • Particle Radiation Oncology Research Center, Research Reactor Institute, Kyoto University
Clinical study - patient Study

DOI: 10.1007/s11060-008-9699-x

Cite this article as:
Miyatake, S., Kawabata, S., Yokoyama, K. et al. J Neurooncol (2009) 91: 199. doi:10.1007/s11060-008-9699-x

Abstract

We have applied boron neutron capture therapy (BNCT) to malignant brain tumors. Here we evaluated the survival benefit of BNCT for recurrent malignant glioma (MG). Since 2002, we have treated 22 cases of recurrent MG with BNCT. Survival time was analyzed with special reference to recursive partitioning analysis (RPA) classification, by Carson et al. (J Clin Oncol 25:2601–2606, 2007). Median survival times (MSTs) after BNCT for all patients and for glioblastoma as on-study histology at recurrence was 10.8 months (n = 22; 95% CI, 7.3–12.8 months) and 9.6 months (n = 19; 95% CI, 6.9–11.4 months), respectively. In our study, MST for the high-risk RPA classes was 9.1 months (n = 11; 95% CI, 4.4–11.0 months). By contrast, the original journal data showed that the MST of the same RPA classes was 4.4 months (n = 129; 95% CI, 3.6–5.4 months). BNCT showed a survival benefit for recurrent MG, especially in the high-risk group.

Keywords

BNCT BPA–PET GBM MG RPA

Supplementary material

11060_2008_9699_MOESM1_ESM.doc (34 kb)
MOESM1 (DOC 33 kb)

Copyright information

© Springer Science+Business Media, LLC. 2008